By Hendra Lukman 
A groundbreaking discovery by researchers at the University of Osaka and their multi-institutional collaborators has identified a specific subset of HLA-DRB1 as a potent and precise target for chimeric antigen receptor (CAR)-based therapies in acute myeloid leukemia (AML), offering a beacon of hope for patients who have relapsed after allogeneic hematopoietic stem cell transplantation (allo-HCT). Published in the prestigious journal Nature Cancer, this research represents a significant leap forward in the quest for highly specific anti-cancer treatments, addressing a critical unmet need in a notoriously challenging hematologic malignancy.
The Persistent Challenge of AML and Relapse
Acute myeloid leukemia (AML) is a heterogeneous and aggressive blood cancer characterized by the rapid proliferation of abnormal myeloid cells in the bone marrow. Despite advancements in treatment modalities, including chemotherapy, targeted therapies, and the life-saving procedure of allo-HCT, a significant proportion of AML patients experience relapse. Allo-HCT, where a patient receives healthy stem cells from a donor, remains a cornerstone of treatment for many AML patients, particularly those with high-risk disease. The underlying principle of allo-HCT is to establish a new immune system in the patient that can recognize and eliminate any residual leukemia cells, a phenomenon known as the graft-versus-leukemia (GvL) effect. However, the efficacy of this GvL effect can wane over time, or the leukemia can evolve to evade immune surveillance, leading to relapse.
The inherent difficulty in developing targeted therapies for AML lies in identifying antigens that are exclusively expressed on leukemia cells while being absent from healthy tissues. This selectivity is paramount to avoid on-target, off-tumor toxicity, a common concern with many immunotherapies. While CAR T-cell therapy has revolutionized the treatment of certain B-cell leukemias and lymphomas, as well as multiple myeloma, its application in AML has been hampered by the lack of truly leukemia-specific targets. Many current CAR targets in AML clinical trials are also found on normal cells, leading to dose-limiting toxicities and limiting their therapeutic potential.
A Strategic Search for a Unique Target
The research team, building on their prior success in identifying tumor-specific targets for multiple myeloma, adopted a similar systematic approach to pinpoint a novel antigen for AML. Their strategy involved screening a vast library of monoclonal antibodies (mAbs) – laboratory-produced molecules designed to bind to specific targets – for their ability to recognize AML cells without interacting with normal blood cells. This meticulous screening process aimed to uncover a "Achilles’ heel" on AML cells that could be exploited by engineered immune cells.
"In our previous work in multiple myeloma, we screened monoclonal antibodies (mAbs) to identify any that could react with human MM samples but not with normal blood cells," stated Shunya Ikeda, the lead author of the study. "We aimed to use that same strategy to find AML-specific antigens. The challenge with AML is its complexity and the presence of antigens on normal hematopoietic stem cells."
The initial phase of the study involved evaluating thousands of mAbs that had been generated against AML cells. Through rigorous filtering, the researchers narrowed down this extensive collection to 32 mAbs that demonstrated specific binding to AML cells. Among these, one particular mAb, designated KG2032, stood out due to its robust and consistent reactivity with AML cells across a substantial portion of patient samples tested – over 50%. This high prevalence of expression suggested that KG2032 was recognizing a molecule of significant therapeutic interest.
Unmasking HLA-DRB1 as the Key
Employing advanced sequencing technologies, the research team was able to identify the precise molecular target of KG2032. Their findings revealed that KG2032 binds to a specific subset of the human leukocyte antigen (HLA) class II molecule, HLA-DRB1. HLA molecules are crucial components of the immune system, responsible for presenting peptides to T cells, thereby initiating an immune response. While HLA molecules are generally found on many cell types, the researchers discovered a critical nuance in the binding of KG2032 to a specific variant of HLA-DRB1.
"Interestingly, we found that KG2032 reacted with a specific HLA-DRB1 subset in which the protein has an amino acid other than aspartic acid in the 86th position," explained Naoki Hosen, the senior author of the article. "KG2032 would therefore only be reactive to AML cells in individuals with mismatched HLA-DRB1, meaning the patient carries this amino acid residue but the allo-HCT donor does not."
This pivotal observation unlocked the potential for a highly targeted therapeutic strategy. The researchers hypothesized that KG2032 could specifically target AML cells in patients who possess a particular variant of HLA-DRB1 that is absent in their allo-HCT donor. This "mismatch" at the 86th position of HLA-DRB1 creates a unique window of opportunity. In essence, the CAR T cells engineered to recognize this specific HLA-DRB1 variant would be directed against leukemia cells that express it, while sparing the patient’s own normal cells (which would also express it) and, crucially, the donor’s healthy cells (which would lack it). This specificity is particularly relevant in the context of allo-HCT, where donor-recipient HLA compatibility is a critical factor.
Engineering a Potent Immunotherapy: KG2032 CAR T and NK Cells
With the identification of HLA-DRB1 as a promising target, the research team proceeded to engineer CAR T cells to express a receptor that recognizes the specific KG2032-binding HLA-DRB1 subset. The CAR construct was designed to incorporate the binding domain of KG2032, allowing the engineered T cells to identify and bind to AML cells expressing the target antigen.
The preclinical evaluation of these KG2032 CAR T cells yielded highly encouraging results. In in vitro cell culture experiments, the engineered T cells demonstrated potent and highly specific killing of AML cells that expressed the target HLA-DRB1 variant. Crucially, these CAR T cells did not exhibit significant reactivity against normal hematopoietic cells, underscoring the specificity of the targeting strategy.
To further validate their findings and assess the potential for systemic toxicity, the researchers conducted in vivo studies using a mouse model of AML. The results were equally impressive. Administration of KG2032 CAR T cells led to a significant reduction in tumor burden and improved survival in the treated mice. Importantly, these mice did not display any overt signs of toxicity, suggesting that the therapy was well-tolerated and did not cause collateral damage to healthy tissues.
Furthermore, the researchers explored the potential of applying this targeting strategy to another type of immune cell: natural killer (NK) cells. CAR-engineered NK cells have emerged as an attractive alternative to CAR T cells, offering potential advantages such as a lower risk of graft-versus-host disease (GvDHD) and the ability to exert anti-tumor effects without prior T-cell activation. The study found that engineered cord blood-derived CAR NK cells expressing the KG2032 target also demonstrated potent and specific anti-AML activity, mirroring the efficacy observed with CAR T cells and further broadening the therapeutic landscape.
Implications and Future Directions
The findings of this study hold profound implications for the treatment of relapsed AML, particularly for patients who have undergone allo-HCT. The ability to target a specific subset of HLA-DRB1, which is often mismatched between a patient and their donor, offers a novel avenue for leveraging the GvL effect more effectively and overcoming resistance mechanisms.
"This finding indicates that HLA-DRB1 can be a potential target in treating certain patients with AML who have relapsed after allo-HCT," the article stated. The specificity of KG2032 for a particular amino acid substitution in HLA-DRB1 means that this therapy could be tailored to a subset of AML patients, identified through HLA typing. This personalized approach aligns with the growing trend in precision medicine, where treatments are customized based on individual patient characteristics.
The success of KG2032 CAR T and NK cells in preclinical models strongly suggests their potential as life-saving interventions. The research team has indicated that clinical trials are actively being planned for both cell types, marking the transition from laboratory discovery to patient care. These trials will be crucial for confirming the safety and efficacy of this novel therapy in humans and for defining the patient populations most likely to benefit.
The broader impact of this research extends beyond AML. The systematic approach used to identify a tumor-specific antigen, even within a highly polymorphic molecule like HLA, could pave the way for similar strategies in other cancers where specific antigen identification has been a bottleneck. The study underscores the power of combining advanced molecular techniques with sophisticated immunotherapeutic engineering to overcome complex biological challenges in cancer treatment.
As the field of immunotherapy continues to evolve, this research offers a compelling example of how a deep understanding of molecular biology and immunology can translate into tangible clinical benefits. The development of KG2032-derived CAR T and NK cells represents a significant stride towards achieving the long-held goal of selectively eradicating cancer cells while preserving the integrity of healthy tissues, offering renewed hope to AML patients facing relapse.